Replies to post #13499 on Sorrento Therapeutics Inc (SRNE)

[1776club]

All true. YeaBut...will Sorrento run into the same wall that they did with Abivertinib, as did Lilly and 20 other companies with "Lack of Diversity" as the test is being done in Shanghai Chest Hospital Shanghai, Shanghai, China.

https://www.clinicaltrials.gov/ct2/results?cond=&term=NCT04878016&cntry=&state=&city=&dist=&Search=Search

[dia76ca]

This small cell lung cancer trial is one of half a dozen trials Sorrento partnered with Lee's Pharma.
Lee’s Pharm is a public biopharma company with over 20 years of operation in China and currently markets 14 products in the PRC.

Sorrento has licensed exclusive rights to Lee’s Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market.

Sorrento has an other PD-L1 drug partnered with a Korean partner. It is in trials in Korea and the US.